Biotech

Biotech Recent News

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Sanofi expands its partnership with Dren Bio in a deal featuring $100 million upfront and up to $1.7 billion tied to a next-generation autoimmune B-cell therapy.
Johnson & Johnson Gets Target Hike, But BofA Flags Modest Pipeline Impact
Johnson & Johnson Gets Target Hike, But BofA Flags Modest Pipeline Impact
BofA raised Johnson & Johnson's price target to $220, citing steady growth, but sees limited upside from its pipeline through 2026.
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and improving risk-reward outlook.
Johnson & Johnson Wins FDA Nod For First Precision Combo For Mutated Prostate Cancer
Johnson & Johnson Wins FDA Nod For First Precision Combo For Mutated Prostate Cancer
FDA approves Johnson & Johnson's Akeega combo for BRCA2 metastatic prostate cancer after Phase 3 data showed major reductions in progression risk.
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for PSVT in 30 years.
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS trial of tolebrutinib missed the primary endpoint in PPMS, ending plans for regulatory filing.
Tenaya Stock Plunges After $60 Million Equity Offering
Tenaya Stock Plunges After $60 Million Equity Offering
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved